Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912571746> ?p ?o ?g. }
- W2912571746 endingPage "1254" @default.
- W2912571746 startingPage "1244" @default.
- W2912571746 abstract "IntroductionAlthough frequent in NSCLC, patients with brain metastases (BMs) are often excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less-selected NSCLC cohort.MethodsData from consecutive patients with advanced ICI-treated NSCLC were collected. Active BMs were defined as new and/or growing lesions without any subsequent local treatment before the start of ICI treatment. Objective response rate (ORR), progression-free survival, and overall survival (OS) were evaluated. Multivariate analyses were performed by using a Cox proportional hazards model and logistic regression.ResultsA total of 1025 patients were included; the median follow-up time from start of ICI treatment was 15.8 months. Of these patients, 255 (24.9%) had BMs (39.2% active, 14.3% symptomatic, and 27.4% being treated with steroids). Disease-specific Graded Prognostic Assessment (ds-GPA) score was known for 94.5% of patients (35.7% with a score of 0–1, 58.5% with a score of 1.5–2.5, and 5.8% with a score of 3). The ORRs with BM versus without BM were similar: 20.6% (with BM) versus 22.7% (without BM) (p = 0.484). The intracranial ORR (active BM with follow-up brain imaging [n = 73]) was 27.3%. The median progression-free survival times were 1.7 (95% confidence interval [CI]: 1.5–2.1) and 2.1 (95% CI: 1.9–2.5) months, respectively (p = 0.009). Of the patients with BMs, 12.7% had a dissociated cranial-extracranial response and two (0.8%) had brain pseudoprogression. Brain progression occurred more in active BM than in stable BM (54.2% versus 30% [p < 0.001]). The median OS times were 8.6 months (95% CI: 6.8–12.0) with BM and 11.4 months (95% CI: 8.6–13.8) months with no BM (p = 0.035). In the BM subgroup multivariate analysis, corticosteroid use (hazard ratio [HR] = 2.37) was associated with poorer OS, whereas stable BMs (HR = 0.62) and higher ds-GPA classification (HR = 0.48–0.52) were associated with improved OS.ConclusionIn multivariate analysis BMs are not associated with a poorer survival in patients with ICI-treated NSCLC. Stable patients with BM without baseline corticosteroids and a good ds-GPA classification have the best prognosis." @default.
- W2912571746 created "2019-02-21" @default.
- W2912571746 creator A5001400077 @default.
- W2912571746 creator A5002994604 @default.
- W2912571746 creator A5004321308 @default.
- W2912571746 creator A5006476106 @default.
- W2912571746 creator A5007163286 @default.
- W2912571746 creator A5009585365 @default.
- W2912571746 creator A5009978511 @default.
- W2912571746 creator A5011984137 @default.
- W2912571746 creator A5023794502 @default.
- W2912571746 creator A5023804337 @default.
- W2912571746 creator A5028596081 @default.
- W2912571746 creator A5030174263 @default.
- W2912571746 creator A5036018448 @default.
- W2912571746 creator A5037144039 @default.
- W2912571746 creator A5038686648 @default.
- W2912571746 creator A5052844644 @default.
- W2912571746 creator A5052958356 @default.
- W2912571746 creator A5055246540 @default.
- W2912571746 creator A5062179226 @default.
- W2912571746 creator A5063827343 @default.
- W2912571746 creator A5071552466 @default.
- W2912571746 creator A5072356002 @default.
- W2912571746 creator A5072927919 @default.
- W2912571746 date "2019-07-01" @default.
- W2912571746 modified "2023-10-18" @default.
- W2912571746 title "Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors" @default.
- W2912571746 cites W1888498899 @default.
- W2912571746 cites W2104347254 @default.
- W2912571746 cites W2123101598 @default.
- W2912571746 cites W2156353875 @default.
- W2912571746 cites W2198093519 @default.
- W2912571746 cites W2200511737 @default.
- W2912571746 cites W2300932108 @default.
- W2912571746 cites W2312481768 @default.
- W2912571746 cites W2416791964 @default.
- W2912571746 cites W2416906314 @default.
- W2912571746 cites W2527905628 @default.
- W2912571746 cites W2528962190 @default.
- W2912571746 cites W2538232731 @default.
- W2912571746 cites W2555516405 @default.
- W2912571746 cites W2567564314 @default.
- W2912571746 cites W2618641368 @default.
- W2912571746 cites W2635951006 @default.
- W2912571746 cites W2753529762 @default.
- W2912571746 cites W2761881389 @default.
- W2912571746 cites W2767214532 @default.
- W2912571746 cites W2769782763 @default.
- W2912571746 cites W2769863426 @default.
- W2912571746 cites W2770085690 @default.
- W2912571746 cites W2772183668 @default.
- W2912571746 cites W2784283849 @default.
- W2912571746 cites W2796582438 @default.
- W2912571746 cites W2797675588 @default.
- W2912571746 cites W2803847828 @default.
- W2912571746 cites W2805354595 @default.
- W2912571746 cites W2806145489 @default.
- W2912571746 cites W2807369789 @default.
- W2912571746 cites W2807431877 @default.
- W2912571746 cites W2809351334 @default.
- W2912571746 cites W2839934168 @default.
- W2912571746 cites W2888599070 @default.
- W2912571746 cites W2890220134 @default.
- W2912571746 cites W2891725776 @default.
- W2912571746 cites W2891812963 @default.
- W2912571746 cites W2897819498 @default.
- W2912571746 cites W4253076228 @default.
- W2912571746 doi "https://doi.org/10.1016/j.jtho.2019.02.009" @default.
- W2912571746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30780002" @default.
- W2912571746 hasPublicationYear "2019" @default.
- W2912571746 type Work @default.
- W2912571746 sameAs 2912571746 @default.
- W2912571746 citedByCount "164" @default.
- W2912571746 countsByYear W29125717462019 @default.
- W2912571746 countsByYear W29125717462020 @default.
- W2912571746 countsByYear W29125717462021 @default.
- W2912571746 countsByYear W29125717462022 @default.
- W2912571746 countsByYear W29125717462023 @default.
- W2912571746 crossrefType "journal-article" @default.
- W2912571746 hasAuthorship W2912571746A5001400077 @default.
- W2912571746 hasAuthorship W2912571746A5002994604 @default.
- W2912571746 hasAuthorship W2912571746A5004321308 @default.
- W2912571746 hasAuthorship W2912571746A5006476106 @default.
- W2912571746 hasAuthorship W2912571746A5007163286 @default.
- W2912571746 hasAuthorship W2912571746A5009585365 @default.
- W2912571746 hasAuthorship W2912571746A5009978511 @default.
- W2912571746 hasAuthorship W2912571746A5011984137 @default.
- W2912571746 hasAuthorship W2912571746A5023794502 @default.
- W2912571746 hasAuthorship W2912571746A5023804337 @default.
- W2912571746 hasAuthorship W2912571746A5028596081 @default.
- W2912571746 hasAuthorship W2912571746A5030174263 @default.
- W2912571746 hasAuthorship W2912571746A5036018448 @default.
- W2912571746 hasAuthorship W2912571746A5037144039 @default.
- W2912571746 hasAuthorship W2912571746A5038686648 @default.
- W2912571746 hasAuthorship W2912571746A5052844644 @default.
- W2912571746 hasAuthorship W2912571746A5052958356 @default.
- W2912571746 hasAuthorship W2912571746A5055246540 @default.